Mirae Asset Global Investments
KNTE

Mirae Asset Global Investments’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Mirae Asset Global Investments’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,200
Closed -$63.4K – 2683
2024
Q1 		$63.4K Buy
+11,200
New +$27.7K ﹤0.01% 2416
2023
Q2 		– Sell
-12,289
Closed -$76.8K – 2723
2023
Q1 		$76.8K Sell
12,289
-29
-0.2% -$177 ﹤0.01% 2481
2022
Q4 		$75.1K Buy
12,318
+16
+0.1% +$130 ﹤0.01% 2492
2022
Q3 		$147K Buy
+12,302
New +$161K ﹤0.01% 2431

Mirae Asset Global Investments's KNTE Position: Q2 2024 in Review

Mirae Asset Global Investments sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 11,200 shares — an estimated $63.4K sold.

Mirae Asset Global Investments first reported a position in KNTE in Q3 2022 and held it in 4 quarters. The position peaked at $147K in Q3 2022. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Mirae Asset Global Investments reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 11,200 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $63.4K.
  • Mirae Asset Global Investments first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Mirae Asset Global Investments's Kinnate Biopharma Inc. Common Stock position peaked at $147K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Mirae Asset Global Investments's 13F filing for Q2 2024, filed 30 Jul 2024.